JP2024524288A5 - - Google Patents

Info

Publication number
JP2024524288A5
JP2024524288A5 JP2023579443A JP2023579443A JP2024524288A5 JP 2024524288 A5 JP2024524288 A5 JP 2024524288A5 JP 2023579443 A JP2023579443 A JP 2023579443A JP 2023579443 A JP2023579443 A JP 2023579443A JP 2024524288 A5 JP2024524288 A5 JP 2024524288A5
Authority
JP
Japan
Prior art keywords
atp
administered
adenosine triphosphate
day
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023579443A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024524288A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/034510 external-priority patent/WO2022271813A1/en
Publication of JP2024524288A publication Critical patent/JP2024524288A/ja
Publication of JP2024524288A5 publication Critical patent/JP2024524288A5/ja
Pending legal-status Critical Current

Links

JP2023579443A 2021-06-22 2022-06-22 アデノシン三リン酸（ａｔｐ）を含む組成物および認知機能に対する使用方法 Pending JP2024524288A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163213378P 2021-06-22 2021-06-22
US63/213,378 2021-06-22
PCT/US2022/034510 WO2022271813A1 (en) 2021-06-22 2022-06-22 Compositions containing adenosine triphosphate (atp) and methods of use for cognitive function

Publications (2)

Publication Number Publication Date
JP2024524288A JP2024524288A (ja) 2024-07-05
JP2024524288A5 true JP2024524288A5 (https=) 2025-06-30

Family

ID=84544774

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023579443A Pending JP2024524288A (ja) 2021-06-22 2022-06-22 アデノシン三リン酸（ａｔｐ）を含む組成物および認知機能に対する使用方法

Country Status (12)

Country Link
US (1) US20240299435A1 (https=)
EP (1) EP4358972A4 (https=)
JP (1) JP2024524288A (https=)
CN (1) CN117835985A (https=)
AU (1) AU2022297444A1 (https=)
CA (1) CA3224861A1 (https=)
CL (1) CL2023003882A1 (https=)
CO (1) CO2024000517A2 (https=)
EC (1) ECSP24004256A (https=)
MX (1) MX2024000145A (https=)
PE (1) PE20241617A1 (https=)
WO (1) WO2022271813A1 (https=)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629329B2 (en) * 2001-06-04 2009-12-08 Tsi Health Sciences, Inc. Method for increasing muscle mass and strength through administration of adenosine triphosphate
US20050261239A1 (en) * 2004-05-23 2005-11-24 Universiteit Van Maastricht Use of ATP for the manufacture of a medicament for treating certain inflammatory conditions, oxidative stress and fatigue
WO2008001494A1 (en) * 2006-06-27 2008-01-03 Kowa Co., Ltd. Pharmaceutical agent for prevention of fatigue and/or recovery from fatigue
US9522161B2 (en) * 2010-10-26 2016-12-20 Advanced Bio Development, Inc. Performance enhancing composition and method of delivering nutrients
PH12022550598A1 (en) * 2010-12-23 2024-03-11 Amazentis Sa Compositions and methods for improving mitochondrial function and treating neurodenegenerative diseases and cognitive disorders
US20140044690A1 (en) * 2012-08-08 2014-02-13 University Of South Florida High-Energy Compounds for Use in Alzheimer's and Other Neurodegenerative Diseases
US10092590B2 (en) * 2012-09-10 2018-10-09 Metabolic Technologies, Inc. Composition of HMB and ATP and methods of use
WO2014106860A2 (en) * 2013-01-03 2014-07-10 Laila Nutraceuticals Synergistic dietary supplement compositions for enhancing physical performance and energy levels
US10888576B2 (en) * 2018-10-08 2021-01-12 Metabolic Technologies, Inc. Composition of HMB and ATP and methods of use
BR112022004108A2 (pt) * 2019-09-05 2022-05-31 Tsi Group Ltd Métodos para aprimorar a absorção gastrointestinal e utilização sistêmica de materiais nutricionais, para aumentar a biodisponibilidade de um material nutricional em um animal e para aprimorar a absorção de um material nutricional em ser humano

Similar Documents

Publication Publication Date Title
EP3630072A1 (en) Methods and compositions for treating excessive sleepiness
RU2010133489A (ru) Применение ингибиторов гамма-секретазы для лечения рака
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
JP2022551696A5 (https=)
JP2018507243A5 (https=)
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
MXPA05012810A (es) Formas de dosis oral de memantina.
RU2007127499A (ru) Таблетированные композиции, содержащие cci-779 в биодоступной при пероральном введении форме
RU2010109359A (ru) Азитромицин для лечения кожных заболеваний
JP2010538066A5 (https=)
JP2022521233A5 (https=)
JP2024542984A5 (https=)
BRPI0510895A (pt) formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
JP2016505050A5 (https=)
RU2011111792A (ru) Применение парацетамола и ибупрофена в лечении
JP2011500589A5 (https=)
JP2022553888A5 (https=)
EP4045058A1 (fr) Utilisation de nictotinamide mononucléotide (nmn) pour la prevention et/ou le traitement de la polyarthrite rhumatoïde et compositions correspondantes
JP2021517128A5 (https=)
JP2024524288A5 (https=)
JP2023517130A5 (ja) Ａｚｄ１６５６又はその薬学的に許容される塩を含む、コロナウイルスによって引き起こされた肺炎及び／又は心筋炎の治療用組成物
JP2023544249A5 (https=)
JP2024531799A5 (https=)
US8268363B2 (en) Pharmaceutical combination preparation containing glycyrrhizine, zinc, and a compound comprising a thiol group or a group that is metabolized thereto